September 22, 2021 5:19pm
The Biostage Chronicles: It never seems to amaze me, the audacity of the “pump/promote” concerning the daily share pricing, having been down -$0.65 most of the session; buys suddenly appeared and then dissipated to close -$0.45 as 3,833 shares traded
Pre-open indication results: 5 Hits and 2 MISS
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing!
Who else is tracking a broad representative index of cell and gene therapy equities – the facts are supported by real numbers?
The Dow closed UP +338.48 points (+1%); the S&P closed UP +41.45 points (+0.95%) while the Nasdaq closed UP +150.45 points (+1.02%)
Henry’omics:
Indexes rebounded Wednesday after the Fed kept rates unchanged, as expected, and indicated that tapering of asset purchases "may soon be warranted," without providing specific details on timing and pace.
- After a volatile start to the day and week.
Referencing this a.m.’s post, “The anticipation of tapering has been a source of consternation for market participants over the last several months as the central bank escalated its discussions around beginning to remove one of the key sources of support to the pandemic-stricken economy.” (Yahoo Finance)
Data Docket: The Fed held benchmark interest rates near zero, but indicated rate hikes could be coming a bit sooner than expected while significantly cutting their economic outlook for this year.
- Existing home sales fell 2% to a seasonally adjusted 5.88 million units in August from a month earlier, according to the National Association of Realtors (NAR). July sales were revised slightly upward to 6 million units. The results exceeded analyst expectations of a 1.7% decline,
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:
- Wednesday opened negative at 14/18, 2 flats and 1 acquired, flipped positive at the mid-day at 18/14, 2 flats and 1 acquired, closing positive at 18/14, 2 flats and 1 acquired;
RegMed Investors’ (RMi) pre-open: “consternation versus constipation. Will the market’s anxiety and sector unease tighten your portfolio’s “bottom”? … https://www.regmedinvestors.com/articles/12105
Pre-open indication results: 5 Hits: < bluebird bio (BLUE +$0.01), CRISP Therapeutics (CRSP +$0.56), Intellia Therapeutics (NTLA +$1.31), Biostage (BSTG -$0.45), Alnylam Pharmaceuticals (ALNY -$1.94)> and 2 MISS: < Global Blood Therapeutics (GBT -$0.86), Regenxbio (RGNX -$1.17)>
The Biostage (BSTG) Chronicles: “The Biostage (BSTG) Chronicles - Maintaining Sell - Is this another Theranos – faking it to not make it?” … https://www.regmedinvestors.com/articles/12087
Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542 … to date:
- Net Income: 3 and Net losses: 23
- Applied Genetic Technologies (AGTC) reports 9/23
Key Metric - volume:
- Sector volume was LOW with 2 of the 18-upside having higher than the 3-month average volume with Non-Existent volume of 2 of 14-downside having higher than the 3-month average volume;
The Biostage (BSTG) Chronicles: WHAT happened to the usual “pump/promote”?
Wednesday closed down -$0.45 with 3,833 shares traded after Tuesday closed up +$0.25 with 654 shares traded after Monday closed down -$0.26 to $3.40 with 563 shares traded.
- Proves my “facts” of the “pump/promote” actions; why hasn’t the SEC questioned who or which entity is buying these shares – there is a definite pattern?
- WERE BSTG’s Q2 8-K and 10-Q filings AUDITED or UNAUDITED for investors?
There are clear winners and losers
Jumping with share pricing momentum:
- Intellia Therapeutics (NTLA), Fate Therapeutics (FATE) - again, AxoGen (AXGN), BioLife Solutions (BLFS), CRISPR Therapeutics (CRSP) to name 5 of the 18 inclining of the 35 covered
Hammered in today’s market:
- Alnylam Pharmaceuticals (ALNY), Regenxbio (RGNX), Sage Therapeutics (SAGE), Global Blood Therapeutics (GBT) -again, Biostage (BSTG) to name 5 of the 14 declining of the 35 covered
Closing flat:
- 2 – Adverum Biotechnologies (ADVM), ReNeuron (RENE’L) and 1 - Stemline Therapeutics (STML) – acquired
Stats:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Wednesday, the IBB closed up +0.02% and XBI closed up +0.28%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Wednesday was down -3.49 points or -14.33% at 20.87
September, the third month of Q3/21:
Wednesday closed positive with 18 advancers, 14 decliners, 2 flat and 1 acquired
Tuesday closed positive with 22 advancers, 9 decliners, 2 flats and 1 acquired
Monday (9/20) closed negative with 1 advancer, 33 decliners and 1 acquired
The BOTTOM LINE: Today, the sector dived, jived and closed up while trading was slim as some stocks pared their losses and many their gains.
Yesterday, the oversold became the overbought; but who were the buyers – the capricious and profit seeking electronic trading” machines”.
Sentiment is languishing even though the sector rebounded.
My issue is the sector seems to be still under pressure.
The stem, cell and gene therapy sector is still seen as vulnerable to extreme moves in either direction, overbought and oversold categories as risk stimulates the susceptibility!
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, the facts and truth need to be recognized!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
